Immunic, inc. reports top-line data from phase 2 caldose-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis and provides corporate update
– trial did not achieve primary endpoint in the ulcerative colitis (uc) population caused by unexpected interference between vidofludimus calcium and concurrent use of corticosteroids – – in uc population without concurrent steroid use, pooled vidofludimus calcium data suggest activity in clinical remission over placebo; counterbalanced by interference observed in the uc population with concurrent steroid use – – company does not plan further development activities in ulcerative colitis without a partner – – focus to remain on ongoing phase 3 development of vidofludimus calcium in multiple sclerosis, and ongoing imu-935 and imu-856 programs with clinical data for both expected in 2022 – – $93.1 million in cash and cash equivalents as of may 31, 2022 expected to fund immunic into the fourth quarter of 2023 – – conference call and webcast, including a corporate update, to be held today, june 2, 2022 at 8:00 am et – new york , june 2, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today reported top-line data from its phase 2 caldose-1 trial of lead asset, vidofludimus calcium (imu-838), the company's selective oral dhodh inhibitor, in patients with moderate-to-severe ulcerative colitis (uc) (clinicaltrials.gov: nct03341962). the trial did not achieve the primary endpoint of clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium versus placebo at week 10.
IMUX Ratings Summary
IMUX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission